<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="/rss.css" type="text/css"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
    xmlns:cc="http://web.resource.org/cc/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:extra="http://www.w3.org/1999/xhtml"
    xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
    <channel rdf:about="http://www.rbej.com/feeds/latestarticles/journal?quantity=&amp;format=rss&amp;version=">
        <title>Reproductive Biology and Endocrinology - Latest Articles</title>
        <link>http://www.rbej.com</link>
        <description>The latest research articles published by Reproductive Biology and Endocrinology</description>
        <dc:date>2013-05-21T00:00:00Z</dc:date>
        <items>
            <rdf:Seq>
                                <rdf:li rdf:resource="http://www.rbej.com/content/11/1/49" />
                                <rdf:li rdf:resource="http://www.rbej.com/content/11/1/48" />
                                <rdf:li rdf:resource="http://www.rbej.com/content/11/1/47" />
                                <rdf:li rdf:resource="http://www.rbej.com/content/11/1/46" />
                                <rdf:li rdf:resource="http://www.rbej.com/content/11/1/45" />
                                <rdf:li rdf:resource="http://www.rbej.com/content/11/1/44" />
                                <rdf:li rdf:resource="http://www.rbej.com/content/11/1/43" />
                                <rdf:li rdf:resource="http://www.rbej.com/content/11/1/42" />
                                <rdf:li rdf:resource="http://www.rbej.com/content/11/1/41" />
                                <rdf:li rdf:resource="http://www.rbej.com/content/11/1/40" />
                            </rdf:Seq>
        </items>
                 <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </channel>
        <item rdf:about="http://www.rbej.com/content/11/1/49">
        <title>VEGF-c expression in an in vivo model of orthotopic endometrial cancer and retroperitoneal lymph node metastasis</title>
        <description>Background:
Retroperitoneal lymph node (RLN) metastasis is an important indicator of endometrial cancer (EC) prognosis. Because vascular endothelial growth factor c (VEGF-c) is known to influence lymphangiogenesis and thereby lymph node metastasis, this study assessed the relationship of VEGF-c mRNA expression with RLN metastasis in EC.
Methods:
The uterine muscularis mucosae of New Zealand white rabbits were inoculated with a VX2 tumor cell suspension after which they were sacrificed at 15, 18, 21, 24, 27 and 30 days. Control groups consisted of those receiving no treatment or an injection of saline. EC and metastatic RLN tissues along with peripheral blood samples were collected, and VEGF-c mRNA expression was evaluated using fluorescence real-time quantitative PCR.
Results:
The establishment of an in vivo model of EC with complete RLN metastasis was pathologically confirmed at day 21 post-injection with VX2 cells. As compared to the control groups, VEGF-c mRNA expression increased significantly over time in the tumor site, RLN, and peripheral white blood cells of EC rabbits. Significantly higher VEGF-c mRNA expression was observed in metastatic RLNs as compared to those without metastasis (P &lt; 0.001). In addition, increased VEGF-c mRNA expression was observed in peripheral white blood cells of rabbits with RLN metastasis (P &lt; 0.002).
Conclusion:
Injection of a VX2 cell suspension is a simple method of establishing an in vivo EC model. VEGF-c may play an important role in the development of EC and its metastasis to RLN and may be useful marker to predict RLN metastasis.</description>
        <link>http://www.rbej.com/content/11/1/49</link>
                <dc:creator>Yong-Wen Huang</dc:creator>
                <dc:creator>Li-Qun Xu</dc:creator>
                <dc:creator>Rong-Zhen Luo</dc:creator>
                <dc:creator>Xin Huang</dc:creator>
                <dc:creator>Teng Hou</dc:creator>
                <dc:creator>Yan-Na Zhang</dc:creator>
                <dc:source>Reproductive Biology and Endocrinology 2013, null:49</dc:source>
        <dc:date>2013-05-21T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1477-7827-11-49</dc:identifier>
                                <prism:require>/content/figures/1477-7827-11-49-toc.gif</prism:require>
                <prism:publicationName>Reproductive Biology and Endocrinology</prism:publicationName>
        <prism:issn>1477-7827</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>49</prism:startingPage>
        <prism:publicationDate>2013-05-21T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.rbej.com/content/11/1/48">
        <title>Proteomic analysis of human spermatozoa proteins with oxidative stress</title>
        <description>Background:
Oxidative stress plays a key role in the etiology of male infertility. Significant alterations in the sperm proteome are associated with poor semen quality. The aim of the present study was to examine if elevated levels of reactive oxygen species cause an alteration in the proteomic profile of spermatozoa.
Methods:
This prospective study consisted of 52 subjects: 32 infertile men and 20 normal donors. Seminal ejaculates were classified as ROS+ or ROS- and evaluated for their proteomic profile. Samples were pooled and subjected to LC-MS/MS analysis through in-solution digestion of proteins for peptide characterization. The expression profile of proteins present in human spermatozoa was examined using proteomic and bioinformatic analysis to elucidate the regulatory pathways of oxidative stress.
Results:
Of the 74 proteins identified, 10 proteins with a 2-fold difference were overexpressed and 5 were underexpressed in the ROS+ group; energy metabolism and regulation, carbohydrate metabolic processes such as gluconeogenesis and glycolysis, protein modifications and oxidative stress regulation were some of the metabolic processes affected in ROS+ group.
Conclusions:
We have identified proteins involved in a variety of functions associated with response and management of oxidative stress. In the present study we focused on proteins that showed a high degree of differential expression and thus, have a greater impact on the fertilizing potential of the spermatozoa. While proteomic analyses identified the potential biomarkers, further studies through Western Blot are necessary to validate the biomarker status of the proteins in pathological conditions.</description>
        <link>http://www.rbej.com/content/11/1/48</link>
                <dc:creator>Rakesh Sharma</dc:creator>
                <dc:creator>Ashok Agarwal</dc:creator>
                <dc:creator>Gayatri Mohanty</dc:creator>
                <dc:creator>Alaa Hamada</dc:creator>
                <dc:creator>Banu Gopalan</dc:creator>
                <dc:creator>Belinda Willard</dc:creator>
                <dc:creator>Satya Yadav</dc:creator>
                <dc:creator>Stefan du Plessis</dc:creator>
                <dc:source>Reproductive Biology and Endocrinology 2013, null:48</dc:source>
        <dc:date>2013-05-20T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1477-7827-11-48</dc:identifier>
                                <prism:require>/content/figures/1477-7827-11-48-toc.gif</prism:require>
                <prism:publicationName>Reproductive Biology and Endocrinology</prism:publicationName>
        <prism:issn>1477-7827</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>48</prism:startingPage>
        <prism:publicationDate>2013-05-20T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.rbej.com/content/11/1/47">
        <title>Epidemiology of polycystic ovary syndrome: a cross sectional study of university students at An-Najah national university-Palestine</title>
        <description>Background:
Polycystic Ovary Syndrome (PCOS) is the most common gynecological endocrinopathy in women of reproductive age. Despite its heavy burden on female reproduction and general health, there is no study regarding PCOS prevalence in Palestine. This study aims to establish prevalence of PCOS among female university students at An-Najah National University-Palestine and to explore its possible risk factors.
Methods:
A cross sectional study was conducted on 137 female students using convenience sampling method for age group (18&#8211;24) years. PCOS cases were identified according to the National Institute of health (NIH) criteria through clinical interview and assessment for participants at the University clinics. Menstrual irregularities regarding cycle and flow were identified and clinical hyperandrogenism was assessed as the self-reported degree of hirsutism using the modified Ferriman Gallwey (mF-G) scoring method of more than 8 score. Biochemical hyperandrogenism for girls with menstrual irregularities was assessed by measuring free testosterone level. Data were analyzed using SPSS version 17 applying descriptive methods; different risk factor relationships were estimated using bivariate analysis and multivariate logistic regression.
Results:
The estimated prevalence of PCOS was 7.3% , acne was the only studied risk factor among others to be statistically significantly related to PCOS patients (OR&#8201;=&#8201;8.430, P-value&#8201;=&#8201;0.015). Clinical Hirsutism was found in 27% of participants, 70% of whom had idiopathic hirsutism.
Conclusions:
Prevalence of PCOS in Palestine seems to be relatively high but similar to other Mediterranean statistics. We recommend further studies using wider age group and larger sample for all parts of Palestine in order to generalize results.</description>
        <link>http://www.rbej.com/content/11/1/47</link>
                <dc:creator>Samar Musmar</dc:creator>
                <dc:creator>Asma Afaneh</dc:creator>
                <dc:creator>Hafsa Mo'alla</dc:creator>
                <dc:source>Reproductive Biology and Endocrinology 2013, null:47</dc:source>
        <dc:date>2013-05-20T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1477-7827-11-47</dc:identifier>
                                <prism:require>/content/figures/1477-7827-11-47-toc.gif</prism:require>
                <prism:publicationName>Reproductive Biology and Endocrinology</prism:publicationName>
        <prism:issn>1477-7827</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>47</prism:startingPage>
        <prism:publicationDate>2013-05-20T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.rbej.com/content/11/1/46">
        <title>Expressions of candidate molecules in the human fallopian tube and chorionic villi of tubal pregnancy exposed to levonorgestrel emergency contraception</title>
        <description>Background:
Cases of ectopic pregnancy (EP) following levonorgestrel (LNG) emergency contraception (EC) failure were reported, however, the effects of LNG on tubal microenvironment or chorionic villi in EP have not yet been documented.
Methods:
Fifty-five women with tubal pregnancy were divided into two groups according to whether LNG-EC was administrated during the cycle of conception. The serum concentrations of beta-hCG, E2 and P were measured. The mRNA and protein expressions of estrogen and progesterone receptors, leukemia inhibitory factor, vascular endothelial growth factor, inducible nitric oxide synthase, and endocannabinoid receptor - CB1 in the ectopic implantation site and chorionic villi were examined.
Results:
Compared to those unexposed to LNG-EC, women with tubal pregnancy exposed to LNG-EC during the cycle of conception had no statistically significances in the serum concentrations of beta-hCG, E2 P, nor in the pathological types of tubal pregnancy or the expressions of ER-alpha, PR, LIF, VEGF, iNOS and CB1.
Conclusions:
The expressions of candidate molecules in the fallopian tube and chorionic villi were not altered by exposure to LNG-EC. A routine therapy with no additional intervention might thus be applied to tubal pregnancy exposed to LNG-EC.</description>
        <link>http://www.rbej.com/content/11/1/46</link>
                <dc:creator>Changxiao Huang</dc:creator>
                <dc:creator>Mei Zhang</dc:creator>
                <dc:creator>Chunxia Meng</dc:creator>
                <dc:creator>Wei Shi</dc:creator>
                <dc:creator>Lulu Sun</dc:creator>
                <dc:creator>Jian Zhang</dc:creator>
                <dc:source>Reproductive Biology and Endocrinology 2013, null:46</dc:source>
        <dc:date>2013-05-20T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1477-7827-11-46</dc:identifier>
                                <prism:require>/content/figures/1477-7827-11-46-toc.gif</prism:require>
                <prism:publicationName>Reproductive Biology and Endocrinology</prism:publicationName>
        <prism:issn>1477-7827</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>46</prism:startingPage>
        <prism:publicationDate>2013-05-20T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.rbej.com/content/11/1/45">
        <title>Effects of resistin on porcine ovarian follicle steroidogenesis in prepubertal animals: an in vitro study</title>
        <description>Background:
Resistin was first reported to be an adipocyte-specific hormone, but recent studies have indicated a connection between resistin and reproductive function. However, it is not yet known if resistin is expressed by the ovary and if it can affect steroidogenesis in ovarian follicles from prepubertal pigs.
Methods:
In this study, using real time PCR, immunoblotting, and ELISA, we quantified resistin expression and concentration in maturing ovarian follicles (small, 3--4 mm; medium, 4--5 mm; large, 6--7 mm) collected from prepubertal pigs. In addition, the dose-responsive effects of recombinant human resistin (0.1, 1, 10, and 100 ng/ml) on steroid hormone (i.e., progesterone [P4], androstendione [A4], testosterone [T], and estradiol [E2]) secretion in culture medium and steroidogenic enzyme (i.e., CYP11A1, 3betaHSD, CYP17A1, 17betaHSD, and CYP19A1) expression in ovarian follicles were determined.
Results:
We observed that resistin gene and protein expression increased significantly (P &lt; 0.05) during follicular growth, with large follicles expressing the highest level of this adipokine. Recombinant resistin also increased P4, A4, and T secretion by up-regulating the steady state levels of CYP11A1, 3betaHSD, CYP17A1, and 17betaHSD. Recombinant resistin had no effects on E2 secretion and CYP19A1 expression in ovarian follicles.
Conclusion:
Our results show resistin expression in ovarian follicles from prepubertal pigs for the first time. We also show that recombinant resistin stimulates steroidogenesis in ovarian follicles by increasing the expression of CYP11A1, 3betaHSD, CYP17A1, and 17betaHSD. The presence of resistin in the porcine ovary and its direct effects on steroidogenesis suggest that resistin is a new regulator of ovary function in prepubertal animals.</description>
        <link>http://www.rbej.com/content/11/1/45</link>
                <dc:creator>Agnieszka Rak-Mardy¿a</dc:creator>
                <dc:creator>Martyna Durak</dc:creator>
                <dc:creator>Ewa ¿ucja Gregoraszczuk</dc:creator>
                <dc:source>Reproductive Biology and Endocrinology 2013, null:45</dc:source>
        <dc:date>2013-05-17T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1477-7827-11-45</dc:identifier>
                                <prism:require>/content/figures/1477-7827-11-45-toc.gif</prism:require>
                <prism:publicationName>Reproductive Biology and Endocrinology</prism:publicationName>
        <prism:issn>1477-7827</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>45</prism:startingPage>
        <prism:publicationDate>2013-05-17T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.rbej.com/content/11/1/44">
        <title>Efficacy of dehydroepiandrosterone to improve ovarian response in women with diminished ovarian reserve: a meta-analysis</title>
        <description>Women with diminished ovarian reserve often respond poorly to controlled ovarian stimulation resulting in retrieval of fewer oocytes and reduced pregnancy rates. It has been proposed that pre-IVF Dehydroepiandrosterone (DHEA) adjuvant therapy may improve ovarian response and pregnancy rates in women with diminished ovarian reserve. This meta-analysis aims to investigate efficacy of DHEA as an adjuvant to improve ovarian response and IVF outcome in women with diminished ovarian reserve. Electronic databases were searched under the following terms: (DHEA) and (diminished ovarian reserve) and/or (poor response).Studies were included if they reported at least one of the following outcomes; clinical pregnancy rate, number of oocytes retrieved, miscarriage rate.We identified 22 publications determining effects of DHEA in clinical trials. Only 3 controlled studies were eligible for meta-analysis.There was no significant difference in the clinical pregnancy rate and miscarriage rates between women pre-treated with DHEA compared to those without DHEA pre-treatment (RR 1.87, 95% CI 0.96-3.64; and RR 0.59, 95% CI 0.21-1.65, respectively). The number of oocytes retrieved (WMD -1.88, 95% CI -2.08, 1.67; P &lt; 0.001) was significantly lower in the DHEA group.In conclusion, based on the limited available evidence from a total of approximately 200 IVF cycles, there are insufficient data to support a beneficial role of DHEA as an adjuvant to controlled ovarian stimulation in IVF cycle. Well-designed, randomised controlled trials as well as more exact knowledge about DHEA mechanisms of action are needed to support use of DHEA in standard practice for poor-responders.</description>
        <link>http://www.rbej.com/content/11/1/44</link>
                <dc:creator>Amarin Narkwichean</dc:creator>
                <dc:creator>Walid Maalouf</dc:creator>
                <dc:creator>Bruce Campbell</dc:creator>
                <dc:creator>Kannamannadiar Jayaprakasan</dc:creator>
                <dc:source>Reproductive Biology and Endocrinology 2013, null:44</dc:source>
        <dc:date>2013-05-16T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1477-7827-11-44</dc:identifier>
                                <prism:require>/content/figures/1477-7827-11-44-toc.gif</prism:require>
                <prism:publicationName>Reproductive Biology and Endocrinology</prism:publicationName>
        <prism:issn>1477-7827</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>44</prism:startingPage>
        <prism:publicationDate>2013-05-16T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.rbej.com/content/11/1/43">
        <title>Intraovarian regulation of gonadotropin-dependent folliculogenesis depends on notch receptor signaling pathways not involving Delta-like ligand 4 (Dll4)</title>
        <description>Background:
In-situ hybridisation studies demonstrate that Notch receptors and ligands are expressed in granulosa cells (GCs) and in the theca layer vasculature of growing follicles. Notch signaling involves cell-to-cell interaction mediated by transmembrane receptors and ligands. This signaling pathway may represent a novel intraovarian regulator of gonadotropin-dependent follicular development to the preovulatory stage. We hypothesized that blocking Notch pathways would disrupt follicular maturation in the mouse ovary.
Methods:
Hypophysectomized CD21 female mice were administered pregnant mare serum gonadotropin (PMSG) for 3 days to stimulate follicular development. In one experiment, a pan-notch inhibitor, compound E, was initiated 2 days prior to and throughout stimulation (n = 10), while in a second experiment, a humanized phage Dll4 blocking antibody, YW152F, was used (n = 5). After sacrifice, ovarian histology, serum estradiol levels and uterine weights were compared to controls. The ovarian morphology was evaluated with hematoxylin/eosin staining and immunohistochemistry was performed for Notch1, Notch2, Notch3, Notch4, Jagged1, Dll4, platelet endothelial cell adhesion molecule (PECAM) and alpha-smooth muscle actin (alpha-SMA) detection.
Results:
We localized specific Notch ligands and receptors in the following structures: Dll4 is specific to theca layer endothelial cells (ECs); Notch1/Notch4 and Jagged1 are expressed in theca layer ECs and vascular smooth muscle cells (VSMCs), whereas Notch3 is restricted to VSMCs; Notch2 is expressed mostly on GCs of small follicles. Administration of a pan-Notch inhibitor, compound E, inhibits follicular development to the preovulatory stage (8.5 preovulatory follicles in treatment vs. 3.4 preovulatory follicles in control, p &lt; 0.01; average number per ovary) with significant secondary effects on ovarian and uterine weight and estradiol secretion in a setting of uninhibited vascular proliferation, but disorganized appearance of ECs and VSMCs. Inhibition of endothelial Notch1 function through the inactivation of its ligand Dll4 with the blocking antibody YW152F induces mild disorganisation of follicular vasculature, but has no significant effect on gonadotropin-dependent folliculogenesis.
Conclusions:
Our experiments suggest that the complete blockage of the Notch signaling pathway with compound E impairs folliculogenesis and induces disruption of gonadotropin stimulated angiogenesis. It seems the mechanism involves Notch1 and Notch3, specifically, causing the improper assembly of ECs and VSMCs in the theca layer, although the potential role of non-angiogenic Notch signaling, such as Jagged2 to Notch2 in GCs, remains to be elucidated.</description>
        <link>http://www.rbej.com/content/11/1/43</link>
                <dc:creator>Vuk Jovanovic</dc:creator>
                <dc:creator>Christopher Sauer</dc:creator>
                <dc:creator>Carrie Shawber</dc:creator>
                <dc:creator>Raul Gomez</dc:creator>
                <dc:creator>Xing Wang</dc:creator>
                <dc:creator>Mark Sauer</dc:creator>
                <dc:creator>Jan Kitajewski</dc:creator>
                <dc:creator>Ralf Zimmermann</dc:creator>
                <dc:source>Reproductive Biology and Endocrinology 2013, null:43</dc:source>
        <dc:date>2013-05-15T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1477-7827-11-43</dc:identifier>
                                <prism:require>/content/figures/1477-7827-11-43-toc.gif</prism:require>
                <prism:publicationName>Reproductive Biology and Endocrinology</prism:publicationName>
        <prism:issn>1477-7827</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>43</prism:startingPage>
        <prism:publicationDate>2013-05-15T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.rbej.com/content/11/1/42">
        <title>Expression analysis of MND1/GAJ, SPATA22, GAPDHS and ACR genes in testicular biopsies from non-obstructive azoospermia (NOA) patients</title>
        <description>Background:
High-throughput studies provide a wide spectrum of genes for use as predictive markers during testicular sperm extraction (TESE) in combination with ICSI. In this work, we used the specimens from testicular biopsies of men with non-obstructive azoospermia who underwent TESE to investigate the expression of spermatogenesis-related genes MND1, SPATA22, GAPDHS and ACR.
Methods:
Testicular biopsy specimens were subdivided into three groups: hypospermatogenesis (HS); maturation arrest (MA); and Sertoli cell-only syndrome (SCO). The levels of expression of the spermatogenesis-related genes MND1, SPATA22, GAPDHS and ACR in the testes were compared among these three groups using the reverse transcription polymerase chain reaction (RT-PCR) technique.
Results:
Analysis of the expression of spermatogenic genes in human testes with abnormal spermatogenesis showed different expression patterns in patients from different groups. Fertilization rate for studied set of patients was 66% and pregnancy rate 29%. For HS group fertilization rate was 72% and pregnancy rate 32%, while for MA group fertilization and pregnancy rates were 54% and 26%, respectively. Fertilization rates in relation to the studied genes were uniformly around 70%, pregnancy rates for ACR and GAPDHS genes were surprisingly low at 6% and 8% correspondingly.
Conclusions:
Analysis of the expression of genes involved in spermatogenesis can be a fast additional test for the level of spermatogenesis in testicular samples.</description>
        <link>http://www.rbej.com/content/11/1/42</link>
                <dc:creator>Andriy Dorosh</dc:creator>
                <dc:creator>Olina Tepla</dc:creator>
                <dc:creator>Eva Zatecka</dc:creator>
                <dc:creator>Lukas Ded</dc:creator>
                <dc:creator>Karel Koci</dc:creator>
                <dc:creator>Jana Peknicova</dc:creator>
                <dc:source>Reproductive Biology and Endocrinology 2013, null:42</dc:source>
        <dc:date>2013-05-15T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1477-7827-11-42</dc:identifier>
                                <prism:require>/content/figures/1477-7827-11-42-toc.gif</prism:require>
                <prism:publicationName>Reproductive Biology and Endocrinology</prism:publicationName>
        <prism:issn>1477-7827</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>42</prism:startingPage>
        <prism:publicationDate>2013-05-15T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.rbej.com/content/11/1/41">
        <title>The new Rapid-i carrier is an effective system for human embryo vitrification at both the blastocyst and cleavage stage</title>
        <description>Background:
The Rapid-i is a new FDA cleared closed carrier for embryo vitrification. The cooling rate of - 1220&#176;C/min is far lower than that reported with open vitrification systems such as the cryoloop (&#8722;15,000&#176;C/min). Little published data is currently available on this device. This study presents our initial clinical data, as well as live birth outcomes, with the Rapid-i. The efficacy of this device for the cryopreservation of cleavage, as well as blastocyst stage human embryos is also analyzed. We further compare outcomes to those achieved with the cryoloop, an &#8220;open&#8221; vitrification system routinely used in our laboratory.
Methods:
Human embryos were vitrified at either the 8&#8211;10 cell stage or else the blastocyst stage. The vitrification protocol was: 7.5% DMSO/7.5% ethylene glycol (EG) (2&#8211;3 min) followed by incubation in 15% DMSO /15% EG (45 sec) before loading on the vitrification carrier. Cryoprotectant was removed during warming by sequential washes in 0.25 M and 0.125 M sucrose in culture medium. Clinical outcome data for frozen cycles between January 2011 and August 2012 were stratified according to carrier and cell stage. The student t-test and chi square test were used to compare results. P value of&#8201;&lt;&#8201;0.05 was considered significant.
Results:
A total of 486 vitrified-warmed embryos were assessed and 92% of them were transferred. The clinical pregnancy rate (CPR) and implantation rate (IR) with Rapid-i vitrified blastocysts were 59% and 49%, versus 47% and 37%, respectively for cleavage stage embryos. This was not statistically different from results with the cryoloop vitrified blastocysts (CPR 46%, IR 38%) nor the cleavage stage vitrified embryos (CPR 49%, IR 35%). To date, there have been 31 deliveries of 34 healthy infants from Rapid-i vitrified embryos, with another 12 pregnancies still on-going.
Conclusions:
The Rapid-i offers an excellent alternative to existing open vitrification devices for embryo cryopreservation at the 8&#8211;10 cell stage as well as the blastocyst stage. Use of this type of &#8220;closed&#8221; sealed system that prevents direct contact between the embryos and liquid nitrogen reduces the potential risk of sample cross-contamination or infection. These preliminary data and live birth outcomes have paved the way toward transitioning to a closed vitrification system in our own IVF program.</description>
        <link>http://www.rbej.com/content/11/1/41</link>
                <dc:creator>Nina Desai</dc:creator>
                <dc:creator>Jeffrey Goldberg</dc:creator>
                <dc:creator>Cynthia Austin</dc:creator>
                <dc:creator>Tommaso Falcone</dc:creator>
                <dc:source>Reproductive Biology and Endocrinology 2013, null:41</dc:source>
        <dc:date>2013-05-15T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1477-7827-11-41</dc:identifier>
                                <prism:require>/content/figures/1477-7827-11-41-toc.gif</prism:require>
                <prism:publicationName>Reproductive Biology and Endocrinology</prism:publicationName>
        <prism:issn>1477-7827</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>41</prism:startingPage>
        <prism:publicationDate>2013-05-15T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.rbej.com/content/11/1/40">
        <title>Measuring thyroid peroxidase antibodies on the day nulliparous women present for management of miscarriage: a descriptive cohort study</title>
        <description>Background:
There has been recent evidence suggesting the presence of anti-thyroid peroxidase antibodies (TPOAb) increases the risk of miscarriage, and levothyroxine can rescue miscarriages associated with TPOAb. We propose the most clinically pragmatic cohort to screen for TPOAb are women presenting for management of a missed miscarriage and have never birthed a liveborn. We measured serum TPOAb among nulliparous women presenting for management of miscarriage, and compared levels with women who have had 2 or more livebirths (and never miscarried). Given its potential role in immunomodulation, we also measured Vitamin D levels.
Methods:
We performed a prospective descriptive cohort study at a tertiary hospital (Mercy Hospital for Women, Victoria, Australia). We measured TPOAb and Vitamin D levels in serum obtained from 118 nulliparous women presenting for management of miscarriage, and 162 controls with 2 or more livebirths (and no miscarriages). Controls were selected from a serum biobank prospectively collected in the first trimester at the same hospital.
Results:
Nulliparous women with 1 or more miscarriages had higher thyroid peroxidase antibody (TPOAb) levels than those with 2 or more livebirths; TPOAb in miscarriage group was 0.3 mIU/L (interquartile range [IR]: 0.2-0.7) vs 0.2 mIU/L among controls (IR 0.0-0.5; p&#8201;&lt;&#8201;0.0001). We confirmed TPOAb levels were not correlated with serum human chorionic gonadotrophin (hCG) concentrations in either the miscarriage or control groups. In contrast, thyroid stimulating hormone, fT3 and fT4 levels (thyroid hormones) either trended towards a correlation, or were significantly correlated with serum hCG levels in the two groups. Of the entire cohort that was predominantly caucasian, only 12% were Vitamin D sufficient. Low Vitamin D levels were not associated with miscarriage.
Conclusions:
We have confirmed the association between miscarriage and increased TPOAb levels. Furthermore, it appears TPOAb levels in maternal blood are not influenced by serum hCG levels. Therefore, we propose the day nulliparous women present for management for miscarriage is a clinically relevant, and pragmatic time to screen for TPOAb.</description>
        <link>http://www.rbej.com/content/11/1/40</link>
                <dc:creator>Mathis Grossmann</dc:creator>
                <dc:creator>Rudolf Hoermann</dc:creator>
                <dc:creator>Claire Francis</dc:creator>
                <dc:creator>Emma Hamilton</dc:creator>
                <dc:creator>Aye Tint</dc:creator>
                <dc:creator>Tu¿uhevaha Kaitu¿u-Lino</dc:creator>
                <dc:creator>Kent Kuswanto</dc:creator>
                <dc:creator>Martha Lappas</dc:creator>
                <dc:creator>Ken Sikaris</dc:creator>
                <dc:creator>Jeffery Zajac</dc:creator>
                <dc:creator>Michael Permezel</dc:creator>
                <dc:creator>Stephen Tong</dc:creator>
                <dc:source>Reproductive Biology and Endocrinology 2013, null:40</dc:source>
        <dc:date>2013-05-14T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1477-7827-11-40</dc:identifier>
                                <prism:require>/content/figures/1477-7827-11-40-toc.gif</prism:require>
                <prism:publicationName>Reproductive Biology and Endocrinology</prism:publicationName>
        <prism:issn>1477-7827</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>40</prism:startingPage>
        <prism:publicationDate>2013-05-14T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
        <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks" />
    </cc:License>
</rdf:RDF>
